Track market-moving stories before they get noisy

Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias
Medtronic continues to strengthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).

"These favorable results reinforce our confidence in the safety and performance of our ablation technologies worldwide. It is very encouraging to see physicians' positive response and real-world evidence that supports effective, safe, and efficient care for patients with a wide range of arrhythmias," said Khaldoun Tarakji, M.D., MPH, Vice President and Chief of Science, Research and Technology, Electrophysiology Therapies at Medtronic.

APEX registry: Sphere-9 real-world outcomes in atrial fibrillation
The APEX global prospective registry analysis included 1,050 patients with AFib treated with the Sphere-9 catheter and Affera Mapping and Ablation System across 28 global sites. The major complication rate was low at 1.1%, with no acute kidney injury, severe coronary spasm or phrenic nerve injury. Major complication rates did not differ significantly between de novo and repeat ablation procedures.

REAL PULSE global registry: PulseSelect real-world safety and performance
The REAL PULSE global prospective registry analysis included 1,160 atrial fibrillation patients treated with the PulseSelect PFA system across 38 global sites. Results were positive, including a 100% acute success rate and a low acute major complication rate of 0.09%.

APEX registry: Expanding evidence in ventricular tachycardia
A separate European APEX registry analysis evaluated use of the Sphere-9 catheter in patients undergoing ablation for VT, demonstrating promising results for the potential of the Sphere-9 catheter and pulsed field ablation in a patient population that can be challenging to treat.

The analysis included 46 patients with ischemic and non-ischemic sustained VT and demonstrated high acute success (87%) and estimated six-month freedom from VT recurrence (75%).
There was no significant difference in long-term freedom from arrhythmia recurrence in ischemic and non-ischemic cardiomyopathy patients.
Six major complications were reported in four patients.

Sphere-9 is CE marked for VT and is investigational only and not approved for VT in the United States. The ventricular ablation indication may not be approved or cleared in all markets.

"As momentum continues to build across our portfolio, it is encouraging to see long-term data support the safety and efficacy profiles of our ablation technologies and the positive impact they are having on procedural workflows," said Felicia Kurz, Vice President and General Manager, Cardiac Ablation Solutions, which is part of the Electrophysiology Therapies business at Medtronic. "We will continue to innovate and strengthen our leadership in cardiac ablation, with a focus on advancing safe, effective and efficient care for patients."

The Medtronic cardiac ablation portfolio offers physicians multiple technologies for patient care, including the Sphere-9 catheter, an all-in-one catheter that combines high-definition mapping with pulsed field and radiofrequency ablation using the Affera mapping and ablation system, and the PulseSelect PFA system, a single-shot solution for pulmonary vein isolation.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit Medtronic.com and follow @Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Leslie Williamson
Public Relations
+1-612-227-5099

Ingrid Goldberg
 Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

Medtronic PLC (NYSE:MDT – Get Free Report) CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medtronic Price Performance NYSE MDT opened at $94.79 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $121.25 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.55. The company has a 50 day moving average price of $91.03 and a two-hundred day moving average price of $85.01. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s payout ratio is presently 70.94%. Hedge Funds Weigh In On Medtronic A number of hedge funds have recently modified their holdings of MDT. WCM Investment Management LLC bought a new stake in Medtronic in the first quarter valued at $965,922,000. First Eagle Investment Management LLC raised its stake in Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares in the last quarter. Cullen Capital Management LLC bought a new position in shares of Medtronic during the second quarter valued at $202,764,000. State Street Corp lifted its holdings in shares of Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after acquiring an additional 1,658,301 shares during the period. Finally, Amundi lifted its holdings in shares of Medtronic by 36.3% during the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after acquiring an additional 1,616,739 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Medtronic Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026 Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up? Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now? Wall Street Analysts Forecast Growth A number of equities research analysts recently issued reports on the stock. UBS Group reiterated a “cautious” rating on shares of Medtronic in a report on Wednesday. Robert W. Baird raised their price objective on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Needham & Company LLC reissued a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Stifel Nicolaus upped their price target on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a report on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $92.00 price objective on shares of Medtronic in a research report on Thursday, September 3rd. Seventeen research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $102.88.

Check Out Our Latest Stock Analysis on MDT

About Medtronic (Get Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

Featured Articles Five stocks we like better than Medtronic Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Medtronic is targeting high-growth markets, with cardiac ablation sales surging 88% worldwide.MDT's hypertension growth gains support from better reimbursement, clinical evidence and hospital adoption.MDT expands MedSurg growth through Hugo robotics and Touch Surgery amid tariff and currency pressures.
Medtronic plc (MDT - Free Report) is expanding its presence in high-growth markets, including cardiac ablation, robotics and structural heart, while advancing the MiniMed separation. Hypertension is a growing focus for the company, aided by improved reimbursement, clinical evidence, hospital adoption and workflow integration. MedSurg growth is supported by robotics, digital surgery and core procedural technologies, with Hugo and Touch Surgery expanding adoption. Meanwhile, Medtronic faces tariff, inflation, product-mix and currency risks that could pressure margins.

Over the past year, this Zacks Rank #3 (Hold) stock has risen 0.1% against the industry’s 26.6% fall and the S&P 500 composite’s 16.6% jump.

The renowned medical device company has a market capitalization of $120.53 billion. Medtronic has an earnings yield of 6.4% compared with the industry’s yield of 2.7%. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.76%.

Let’s delve deeper.

Tailwinds for MDTStrategic Focus to Capture Several Growth Markets: Medtronic is expanding in cardiac ablation, neuromodulation, diabetes technologies, surgical robotics and other faster-growing adjacencies. This approach lets the company concentrate investment in categories where differentiated innovation can support multi-year growth. In the first quarter of fiscal 2027, organic revenues rose 13.7%, including an estimated 670-basis-point (bps) benefit from the extra selling week. Excluding that benefit, management said the quarter delivered its best performance in nearly eight years outside pandemic-related comparisons. CAS remained the clearest growth driver, increasing 88% worldwide as Affera and Sphere-9 adoption expanded.

Medtronic also completed the Scientia Vascular and SPR Therapeutics acquisitions, which are expected to contribute more than $150 million of inorganic fiscal 2027 revenues. Both operate in markets with annual growth rates above 20%, increasing exposure to faster-growing categories. Strategic investments in Cornerstone Robotics and Pi-Cardia expand Medtronic’s exposure to robotics and structural heart, while the MiniMed separation remains on track for completion before fiscal year-end.

Image Source: Zacks Investment Research

Hypertension, A New Focus Area: Medtronic’s Hypertension business is building the Symplicity Spyral renal denervation franchise as reimbursement, clinical evidence and workflow integration improve. Procedure momentum increased following the final Medicare National Coverage Determination. At the end of fiscal 2026, average weekly procedures doubled after the decision, while the franchise annualized at about $100 million. In the first quarter of fiscal 2027, management cited progress in access, market development and adoption, with more hospitals approaching Medtronic about establishing programs.

The SPYRAL AFFIRM clinical trial was accepted as a late-breaker for TCT in fall 2026, extending the evidence base. The company also expects to launch a transradial catheter in the second half of fiscal 2027, which should make the therapy easier to integrate into established interventional workflows.

MedSurg Growth Prospects Remain Favorable: Medical Surgical is benefiting from broader adoption of robotics, digital surgery and core procedural technologies. First-quarter fiscal 2027 revenues increased 10.2% organically compared with 2.9% growth in fiscal 2026. Surgical & Endoscopy rose 9%, supported by Advanced Energy, Wound Management, Endoscopy and a larger Hugo contribution. Management expects Hugo to exceed 50,000 completed procedures by fiscal 2027 year-end, with procedure growth running at more than twice the market rate.

Touch Surgery is now used in more than 1,500 operating rooms globally, while FDA clearance for Touch Surgery Aide expands the digital surgery platform. The Cornerstone Robotics agreement broadens Medtronic’s robotics offering and is expected to contribute to growth and margins beginning in fiscal 2028.

Downsides for MDTMacroeconomic and Margin Risks Persist: Medtronic remains exposed to changing global trade policies, inflation and geopolitical disruption, which can raise operating costs and complicate margin recovery. Tariffs were only a slight drag in first-quarter fiscal 2027 as payments were largely offset by refunds, but the benefit may not persist as trade policies evolve. Product mix also remained unfavorable by 50 bps, mainly due to Diabetes and CAS. Pricing and cost of goods sold (COGS) efficiency provided offsets during the quarter, yet continued investment in commercialization and portfolio expansion could absorb part of those gains.

Exposure to Currency Movement: Medtronic’s large international presence leaves reported results sensitive to exchange rates. Fiscal 2027 guidance now assumes a $50 million to $150 million revenue drag from foreign exchange, while the EPS impact is expected to be neutral to a 1% benefit.

MDT Stock Estimate TrendThe Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has increased 1 cent to $5.98 in the past 30 days.

The consensus estimate for fiscal 2027 revenues is pegged at $38.97 billion, implying a 7.2% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .

Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 3.1% compared with the industry’s 26.6% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%. 

PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 19.1% compared with the industry’s 26.5% decline over the past year.

Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.1% compared with the industry’s 7.8% growth over the past year.

NorthCrest Asset Manangement LLC grew its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 14.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 105,147 shares of the medical technology company’s stock after buying an additional 13,074 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Medtronic were worth $9,227,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in MDT. WCM Investment Management LLC acquired a new stake in Medtronic during the 1st quarter worth $965,922,000. First Eagle Investment Management LLC grew its stake in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after acquiring an additional 3,739,288 shares during the period. Cullen Capital Management LLC acquired a new position in Medtronic in the second quarter valued at about $202,764,000. State Street Corp increased its holdings in shares of Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after acquiring an additional 1,658,301 shares in the last quarter. Finally, Amundi increased its holdings in shares of Medtronic by 36.3% in the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after acquiring an additional 1,616,739 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In A number of equities research analysts have recently commented on MDT shares. Truist Financial reaffirmed a “hold” rating and set a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. UBS Group boosted their price objective on Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Stifel Nicolaus increased their target price on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research note on Wednesday, September 2nd. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $92.00 target price on shares of Medtronic in a report on Thursday, September 3rd. Eighteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $102.88.

Get Our Latest Report on MDT Insider Buying and Selling at Medtronic In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is owned by corporate insiders.

More Medtronic News Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said its MiniMed exchange offer was oversubscribed and that it will exchange all of its remaining 252.8 million MiniMed shares. The transaction simplifies Medtronic’s portfolio and allows the company to focus more directly on its core medical-device operations. Medtronic Announces Preliminary Results of MiniMed Group Exchange Offer Positive Sentiment: The MiniMed offer had an 18.3% proration rate, indicating substantial investor demand to participate in the exchange. The result provides further clarity on the ownership transition and separation. Medtronic Reports 18.3 Percent MiniMed Proration Positive Sentiment: BTIG Research maintained a Buy rating while trimming its price target modestly to $99 from $100, still implying meaningful upside from the stock’s recent level. Medtronic Price Target Cut by BTIG Research Positive Sentiment: A new industry report projects the global bioelectronic-medicine device market to expand at approximately a 17% annual rate through 2030. Medtronic’s participation in neuromodulation and closed-loop technologies could provide a favorable long-term demand backdrop, although the report is not company-specific. Global Bioelectronic Medicine Device Market Report Neutral Sentiment: Medtronic’s valuation and improving growth outlook are attracting attention after a period of underperformance versus the broader market. The investment case depends on whether operational improvements can produce more consistent growth. Negative Sentiment: Short interest in Medtronic increased, signaling that more investors are betting against the shares and potentially creating future selling pressure. Medtronic Sees Increase in Short Interest Medtronic Stock Up 3.5% MDT stock opened at $91.61 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The stock has a market capitalization of $117.18 billion, a P/E ratio of 22.56, a P/E/G ratio of 2.02 and a beta of 0.55. The business has a 50-day moving average of $90.38 and a 200-day moving average of $84.80. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period last year, the company earned $1.26 earnings per share. Medtronic’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Stories Five stocks we like better than Medtronic Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Medtronic (MDT +3.12%), one of the world's largest medical device makers, raised its dividend for the 49th consecutive year this June. If it raises its dividend again next year, it will cross the 50-year threshold required for becoming a Dividend King.

But over the past five years, Medtronic's stock has declined 31%. Even with reinvested dividends, it delivered a negative total return of 19%. Let's see why Medtronic's stock slumped, and why it might be worth buying as an income-generating turnaround play.

Image source: Getty Images.

What happened to Medtronic? Medtronic was once considered a reliable blue chip stock. But in fiscal 2023 and fiscal 2024 (which ended in April 2024), its EPS declined as it struggled with supply chain constraints, inflation, forex headwinds, a lumpy recovery in elective procedures after the pandemic, and regulatory hurdles for its diabetes unit. It also faced tougher competition, quality-control issues, and the rise of GLP-1 drugs, which could reduce demand for certain medical procedures.

Medtronic spun off and restructured some of its lower-margin businesses to offset that pressure, but those near-term costs reduced its net income and EPS. In fiscal 2025 and fiscal 2026, its EPS grew again as its component costs normalized, its new diabetes products were approved, and it expanded its higher-growth cardiovascular and neuroscience businesses. It also completed the spin-off of its diabetes unit, MiniMed (MMED +3.30%), this March.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

3.12

%) $

2.67

Current Price

$

88.18

Why is Medtronic worth buying? In fiscal 2026, Medtronic's revenue grew 8.4% (5.8% organically), marking its strongest top-line growth in a decade. That acceleration was mainly driven by its cardiovascular business, which grew 9.3% organically and accounted for over 38% of its enterprise revenue. All of Medtronic's other business segments also grew organically.

Medtronic expect its organic revenue to rise 7.25%-7.75% in fiscal 2027. From fiscal 2026 to fiscal 2029, analysts expect its reported revenue and EPS to grow at CAGRs of 5% and 15%, respectively. At $87 per share, it still looks like a bargain at 18 times this year's earnings.

Medtronic pays a forward dividend yield of 3.4%. It has plenty of room to raise that payout, which only consumed 70% of its EPS and 60% of its free cash flow (FCF) over the past 12 months. So when more investors notice that Medtronic's business is growing again and it's on track to become a Dividend King next year, it could finally command a higher valuation.

MassMutual Private Wealth & Trust FSB increased its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 14.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 149,708 shares of the medical technology company’s stock after buying an additional 19,315 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Medtronic were worth $12,918,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after purchasing an additional 838,220 shares in the last quarter. State Street Corp raised its stake in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after buying an additional 1,658,301 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after buying an additional 1,419,730 shares in the last quarter. Capital Research Global Investors lifted its holdings in Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after buying an additional 3,880,174 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 0.1% Shares of Medtronic stock opened at $86.31 on Monday. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock has a market cap of $110.40 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 1.97 and a beta of 0.55. The company has a 50-day moving average of $90.15 and a two-hundred day moving average of $84.76.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The company’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year. Medtronic Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling In other Medtronic news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades A number of research analysts have recently commented on MDT shares. Weiss Ratings upgraded Medtronic from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, September 4th. Bank of America boosted their target price on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Evercore set a $105.00 price target on Medtronic in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 price target on shares of Medtronic in a research note on Thursday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Nineteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $103.92.

Get Our Latest Stock Analysis on Medtronic

More Medtronic News Here are the key news stories impacting Medtronic this week:

Positive Sentiment: TD Cowen reiterated a “Buy” rating on Medtronic, providing an analyst-confidence signal for the medical-device maker. Medtronic Earns Buy Rating from TD Cowen Positive Sentiment: The FDA granted breakthrough-device designation to Medtronic’s below-the-knee drug-coated balloon, potentially accelerating regulatory interaction and supporting the company’s peripheral vascular pipeline. Medtronic Receives Breakthrough Designation Positive Sentiment: The American Medical Association approved Category I CPT codes for the Altaviva tibial neuromodulation device and Symplicity Spyral renal-denervation system. The codes become effective in January 2028 and could improve reimbursement visibility and adoption over the long term. Medtronic CPT Code Approvals Positive Sentiment: New regulatory clearances for cardiac mapping and ablation software may strengthen Medtronic’s competitive position in the growing pulsed-field ablation market. Medtronic Cardiac Software Clearances Neutral Sentiment: A commentary argues that Medtronic’s dividend and defensive healthcare exposure could remain attractive if inflation and interest rates stay elevated, but it does not represent a new company-specific catalyst. Inflation and Dividend Stocks Neutral Sentiment: An investment opinion says Medtronic’s long-term strategy could still appeal to investors, although Johnson & Johnson’s stronger historical performance highlights execution concerns. Johnson and Johnson Compared With Medtronic Negative Sentiment: The $4 billion tax-free MiniMed exchange offer appears to be losing investor appeal. Reduced participation could make the split-off a weaker near-term catalyst and leave shareholders focused on execution and valuation risks. Medtronic MiniMed Exchange Offer Negative Sentiment: Medtronic’s stock has declined since its latest earnings report, with investors apparently looking for stronger forward earnings momentum despite the prior quarterly revenue and EPS beat. Medtronic Stock Since Earnings Negative Sentiment: Put-option volume was about 45% above average, indicating increased downside hedging or bearish positioning around MDT. Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Featured Articles Five stocks we like better than Medtronic Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam? The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers? MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning? Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension 

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. The new codes, which will replace existing Category III codes, are effective January 2028.

Category I CPT® codes are permanent codes assigned to procedures the AMA has determined are well established, widely performed by physicians across the United States (U.S.), and supported by robust clinical evidence, in addition to other criteria identified in the application process. While a Category I CPT® code establishes a permanent code and can help support physician payment and inform commercial payer coverage decisions, it does not determine coverage, reimbursement, clinical superiority, or patient access.

"These Category I approvals reflect the robust clinical evidence and physician adoption for innovative solutions addressing critical gaps in care and unmet patient needs," said Lindsay Bockstedt, vice president of health economics, policy, and reimbursement at Medtronic. "The decision by AMA represents meaningful progress in the reimbursement pathway for these technologies, as Medtronic remains committed to reducing barriers to broader adoption and patient access. We're grateful to the stakeholders and clinical community whose work made this possible."

The AMA approved new Category I CPT® codes applicable to procedures associated with the following Medtronic technologies:

Altaviva™ Implantable Tibial Neuromodulation Device
The Altaviva™ device was approved by the U.S. Food and Drug Administration (FDA) in September 2025, for the treatment of urge urinary incontinence (UUI) – a condition that impacts 16 million adults in the U.S. 1 The Altaviva™ device is indicated for treatment of UUI in patients who failed or could not tolerate more conservative treatments. The device is approximately half the length of a stick of chewing gum and is placed under the skin near the ankle in a minimally invasive procedure.2 The device delivers stimulation to the tibial nerve to help restore communication between the bladder and brain to improve bladder leakage symptoms. 3-4 Unlike some other treatment options, the Altaviva™ device does not require imaging for implantation and only needs local anesthesia, and it can be activated the same day as the procedure. The system is designed to provide patients with a simple, long-lasting treatment experience, including an expected 15 years of therapy under expected therapy settings. The Altaviva™ device is also MRI-compatible from the start5, offering patients peace of mind for future medical imaging needs.

Symplicity Spyral™ Renal Denervation System
The Symplicity Spyral renal denervation (RDN) system, finalized for Medicare coverage in October 2025, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure. After sedation, the doctor inserts a single thin tube (known as a catheter) into the artery leading to the kidney. Once the tube is in place, the doctor administers energy to the system to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind. The Medtronic SPYRAL HTN global clinical program is the most comprehensive clinical program studying RDN in more than 5,000 patients in the presence and absence of medication, and with high baseline cardiovascular risk, and is backed by experience in over 40,000 patients globally.6-13 

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

CPT® codes, descriptions and other data only are copyright 2025 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014 Cameron AP, Chung DE, Dielubanza EJ et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder (2024). J Urol. 2024;212:11-20.   Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromod. 2023;27:256-266. Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder - techniques and efficacy. Int Urogynecol J. 2020;31:865–70. M028929C001 RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N Medtronic data on file, RDN Catheter Historical Data, Feb 2025. Data includes both Symplicity Flex and Symplicity Spyral. Kandzari DE, Townsend RR, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023 Nov 7;82(19):1809-1823. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020 May 2;395(10234):1444-1451.  Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in asian patients -. Circ J. 2015;79(6):1222–1229. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial renal denervation for resistant hypertension. N Engl J Med. April 10, 2014;370(15):1393–1401. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFFMED): a randomised, sham-controlled, proof-of-concept trial. Lancet. November 11, 2017;390(10108):2160–2170. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–629. Medtronic data on file, RDN Catheter Historical Data, September 2026. Data includes both Symplicity Flex and Symplicity Spyral. Contacts:

Justin Paquette

Ingrid Goldberg

Public Relations

Investor Relations

+1- 612-271-7935

+1-763-505-2696

SOURCE Medtronic plc

FDA clearance and CE Mark for latest Affera™ Prism-2 Mapping Software expand cardiac mapping capabilities

CE Mark for PulseSelect ProxBox™ Adapter with Proximity Indicator software adds real-time tissue proximity feedback

, /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug Administration (FDA) clearance and CE Mark for the latest Affera™ Prism-2 Mapping Software. The company also obtained CE Mark for the PulseSelect ProxBox™ Adapter with Proximity Indicator software. These milestones expand integrated mapping and tissue-proximity capabilities across the Medtronic cardiac ablation portfolio.

"Innovation in mapping software is essential to realizing the full potential of cardiac ablation technologies and supporting the precision physicians seek during procedures," said Khaldoun Tarakji, MD, MPH, vice president and chief medical officer, Cardiac Ablation Solutions at Medtronic. "We are integrating catheters, hardware and software to give physicians a more connected experience and help improve care for patients with heart rhythm disorders."

Affera Mapping and Ablation System with Prism-2 Software
The Affera Prism-2 Mapping Software helps physicians create detailed three-dimensional maps of the heart's electrical activity during cardiac ablation procedures for arrhythmias, or abnormal heart rhythms.

The software uses magnetic and impedance-based tracking to display the location of specialized and conventional diagnostic catheters, including coronary sinus catheters, on a three-dimensional map. This capability can support procedures that use little or no fluoroscopy, reducing reliance on X-ray imaging during cardiac ablation.

Recent software enhancements add advanced cardiac mapping tools to the Affera system, including:

Beat Matching, which helps physicians compare heartbeats and identify those that have abnormal signals. Pace Tagging, which compares heartbeats and marks locations when pacing is performed during a procedure. Improvements to the system's internal pacing stimulator, which assists with cardiac mapping and procedural workflow. Together, these tools can help physicians visualize, analyze and compare the heart's electrical activity, supporting efficient mapping and informed decision-making during cardiac ablation procedures.

The Affera Mapping and Ablation System is the platform used with the Sphere-9™ Catheter, an all-in-one catheter that combines high-definition mapping with dual-energy pulsed field and radiofrequency ablation.

PulseSelect PFA System with Proximity Indicator
The PulseSelect ProxBox™ Adapter with Proximity Indicator software adds real-time, impedance-based feedback to the PulseSelect™ pulsed field ablation (PFA) System. The feedback helps physicians assess whether the catheter is near the targeted heart tissue before energy is delivered.

The PulseSelect PFA System was the first PFA catheter approved by the FDA and is used in more than 60 countries.

"Software excellence is a priority across our electrophysiology business and is central to the integrated experience physicians expect," said Rebecca Seidel, senior vice president and president, Electrophysiology Therapies at Medtronic. "These regulatory milestones advance our software capabilities alongside the continued expansion of our cardiac ablation portfolio."

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit Medtronic.com and follow @Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Leslie Williamson
Public Relations
+1-612-227-5099

Ingrid Goldberg
Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

Wall Street is a fickle place, with investor emotions often shifting quickly. But sometimes, somewhat ironically, investor opinions are stubbornly hard to change. That's likely what's behind Jim Cramer's description of Medtronic (MDT -0.96%) as a "quandary." Here's the backstory and why long-term dividend investors may want to reevaluate their opinion of this medical device giant right now.

Medtronic's fate wasn't shocking Medtronic is an industry-leading medical device maker, with a market cap of roughly $115 billion. A few years ago, the company's growth slowed to a crawl, and a bloated business made decision-making more difficult. This type of thing happens to large companies over time. Investors sold the stock in favor of more nimble businesses. From its 2021 high to its 2023 low, Medtonic's stock lost nearly half of its value.

Image source: Getty Images.

However, the company didn't stick its head in the sand and hope for the best. It began revamping its business by selling assets, investing in technology, and streamlining operations. The goal was pretty simple: focus on its highest growth and most profitable businesses to get the company growing again. The improvements are starting to take shape.

In fiscal 2026, Medtronic delivered its highest annual revenue growth in 10 years. It has new products coming online, including a surgical robot, that offer material long-term growth opportunities. And the dividend is still growing, with the company just one year away from Dividend King status despite the weak patch. Add in a well-above-market 3.1% dividend yield, and you can see why dividend investors would want to look into Medtronic today.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-0.96

%) $

-0.88

Current Price

$

90.87

Wall Street isn't giving Medtronic much credit Jim Cramer's description of Medtronic as a quandary likely reflects that, despite improved results, the stock is still down 30% from its 2021 high. Its price-to-sales and price-to-earnings ratios are both below their five-year averages. Even after reporting strong fiscal first-quarter 2027 results, including nearly 14% revenue growth and a guidance raise after just a single quarter, Wall Street seems to still be stuck in a "show me" mood.

That said, it looks like the company is already showing that it has turned a corner, but investors are not giving it any credit for the improvement. So, if you are a dividend lover, you might want to get to know Medtronic now, before Wall Street changes its mind. While investors can be poor judges of value over short periods, they tend to get things right over long periods. Taking advantage of "quandaries" like Medtronic can both increase the income you generate and lead to attractive long-term capital growth.

Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S.

, /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system. The clearance expands the instruments available on the Hugo RAS system and brings Medtronic's trusted vessel-sealing technology to U.S. surgeons performing robotic-assisted procedures.

The U.S. FDA has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system.

LigaSure™ technology has been used in more than 45 million surgical procedures worldwide. As robotic-assisted surgery adoption grows in the U.S., surgeons increasingly expect the same trusted energy instruments in a robotic workflow that they rely on in open and laparoscopic settings. The LigaSure RAS Maryland instrument meets that expectation, pairing a versatile robotic platform with vessel-sealing technology surgeons already know.

"Vessel sealing sits at the center of how surgeons work through the most demanding moments of a procedure, and surgeons have trusted LigaSure to do it across open and laparoscopic surgery for decades," said Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing surgeon. "Bringing that same performance to the Hugo RAS system in the U.S. means surgeons carry the confidence and control they already rely on into their robotic-assisted cases."

The Hugo RAS system is cleared for use in urologic surgical procedures in the U.S. and is in commercial use at a growing number of leading health systems and hospitals across the country. The company is continuing to progress its plans to expand Hugo indications to a broad range of soft-tissue surgical procedures in the U.S., including general and gynecologic surgical procedures. Outside the U.S., the Hugo RAS system has positively impacted the lives of tens of thousands of patients across more than 35 countries, spanning more than 50 different surgical procedures within urology, general, and gynecology indications.

Designed exclusively for use with the Valleylab™ FT10 energy platform on the Hugo™ RAS system, the LigaSure™ RAS Maryland instrument seals and cuts vessels, thick tissue, and lymphatics up to and including 7 mm in diameter, sealing vessels in approximately 2 seconds while minimizing thermal spread to surrounding tissue. As the first-ever robotic-driven LigaSure™ instrument, it incorporates vessel-sealing technology used in more than 45 million procedures across 65+ countries over the last two decades. The LigaSure RAS Maryland instrument was introduced on the Hugo™ RAS system in Europe in 2025 following CE Mark.

The addition of the LigaSure™ RAS Maryland instrument reflects Medtronic's commitment to meeting surgeons' needs across open, laparoscopic, and robotic-assisted surgical modalities, giving surgeons and health systems the choice and partnership to meet each patient's unique needs and build successful surgery programs.

Learn more at medtronic.com/LigaSureOnHugo.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777

Ingrid Goldberg
Investor Relations
+1-763-505-2696

SOURCE Medtronic plc

, /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn. If the exchange offer is oversubscribed, Medtronic intends to exchange all of Medtronic's remaining interest in MiniMed (an additional 27,452,053 shares of MiniMed common stock), without extending the exchange offer period. In the exchange offer, Medtronic shareholders will have the opportunity to exchange their Medtronic ordinary shares for shares of MiniMed common stock, subject to the terms of the offer.

Medtronic currently owns approximately 89.86% of the total outstanding shares of MiniMed common stock. If the exchange offer (including all related transactions) is effectuated, Medtronic will no longer hold an equity stake in MiniMed.

"With the exchange offer underway, our separation from Medtronic is entering the final stage," said Que Dallara, Chief Executive Officer of MiniMed. "It does not change who we serve, but it gives us complete autonomy over our capital allocation, our product roadmap, and our speed. Independence does not make the job easier; it simply means our execution is entirely in our own hands."

This announcement is for informational purposes only and is neither an offer to sell or an offer to buy any securities nor a recommendation as to whether investors should participate in the exchange offer. The offer is made solely by the prospectus referenced below.

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated timing and benefits of the exchange offer, Medtronic's ability to satisfy the necessary conditions to consummate its separation of MiniMed, Medtronic's and MiniMed's anticipated financial results, all other statements in this communication that are not historical facts, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, the Registration Statement referred to below, including the Prospectus forming a part thereof, the Schedule TO, and other exchange offer documents filed by Medtronic or MiniMed, as applicable, with the SEC. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. MiniMed undertakes no obligation to update forward-looking statements or any of the information contained in this press release.

Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to sell or exchange, a solicitation of an offer to buy or exchange any securities, nor a recommendation as to whether investors should participate in the exchange offer. There shall be no solicitation, offer, sale or exchange of any securities in any jurisdiction in which such solicitation, offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. MiniMed has filed with the SEC a registration statement on Form S-4 (the "Registration Statement") that includes a prospectus ("Prospectus"). The exchange offer is made solely by the Prospectus. The Prospectus contains important information about the exchange offer, Medtronic, MiniMed and related matters, and Medtronic has delivered the Prospectus to holders of Medtronic ordinary shares. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING ANY INVESTMENT DECISION, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. None of Medtronic, MiniMed or any of their respective directors or officers or the dealer managers appointed with respect to the exchange offer makes any recommendation as to whether you should participate in the exchange offer.

Medtronic has filed with the SEC a Schedule TO, which contains important information about the exchange offer.

Holders of Medtronic ordinary shares may obtain copies of the Prospectus, the Registration Statement, the Schedule TO and other related documents, and any other information that Medtronic and MiniMed file electronically with the SEC free of charge at the SEC's website at http://www.sec.gov. Holders of Medtronic ordinary shares may also obtain a copy of the Prospectus by clicking on the appropriate link at http://www.dfking.com/MDTSeparation.

Medtronic has retained D.F. King & Co., Inc. as the information agent for the exchange offer. To obtain copies of the exchange offer Prospectus and related documents, or for questions about the terms of the exchange offer or how to participate, you may contact the information agent at +1-877 361-7972 (toll-free for shareholders) or +1-646 845-0146 (banks, brokers, and all others outside the United States).

SOURCE MiniMed

Key Takeaways Medtronic's organic growth broadened across Cardiovascular, Medical Surgical and Neuroscience.Medtronic raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75%.Medtronic faces margin sensitivity, currency exposure and portfolio execution demands. Medtronic plc (MDT - Free Report) is entering fiscal 2027 with broader revenue growth, higher earnings guidance and a valuation near its historical norm. Those positives improve the investment case, but they do not remove questions around margins, foreign exchange and execution.

The stock therefore sits between improving fundamentals and still-elevated operating risk. Investors have more evidence that growth is becoming durable, yet the current setup still argues for selectivity rather than an aggressive stance.

Medtronic’s Growth Case Is Getting StrongerFiscal 2027 first-quarter organic revenue increased 13.7%, although the extra selling week contributed about 670 basis points to growth. Cardiovascular rose 18.9% organically, Medical Surgical gained 10.2% and Neuroscience advanced 9.3%, showing that performance was not confined to one franchise.

Cardiac Ablation Solutions remained a major driver, rising 88% worldwide, while Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical also delivered solid growth. Management raised full-year organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%, reinforcing expectations for a stronger fiscal year.

Image Source: Zacks Investment Research

MDT Still Faces Margin and Execution RisksThe margin path remains less straightforward. Product mix was unfavorable by 50 basis points in the first quarter, mainly because of Diabetes and Cardiac Ablation Solutions. Adjusted operating margin expanded only 10 basis points to 23.7% as Medtronic continued spending on commercialization, acquisitions and growth platforms.

Tariffs were a slight headwind because payments were largely offset by refunds, but management has not assumed future refunds in its outlook. Foreign exchange is expected to create a $50-$150 million revenue headwind for fiscal 2027. The planned MiniMed separation before fiscal year-end adds another execution variable.

Medtronic Trades Near Its Five-Year Median MultipleMedtronic trades at 15.42X forward 12-month earnings, close to its five-year median of 15.72X. That level is below the cited sub-industry multiple of 16.92X, the Medical sector’s 21.30X and the S&P 500’s 20.10X.

Image Source: Zacks Investment Research

The discount offers some valuation support, but it is not large enough to make execution concerns irrelevant. With the stock already up 17.4% in the past three months, further upside may depend more on sustained growth and margin delivery than on multiple expansion.

MDT’s Earnings Outlook Supports a Hold-or-Buy DebateAdjusted first-quarter earnings of $1.45 per share increased 15.1% year over year and beat the Zacks Consensus Estimate by 4.3%. Medtronic raised fiscal 2027 adjusted earnings guidance to $5.94-$6.00, while the consensus estimate is $5.96 for the current fiscal year and $6.36 for fiscal 2028.

Competition remains active in key growth markets. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026, while Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same period, underscoring the intensity around cardiac ablation and related technologies.

Medtronic’s Scores Favor SelectivityThe bottom line is that Medtronic’s operating picture has improved enough to support continued interest, but the risk-reward balance is not one-sided. Better revenue breadth and a firmer earnings outlook are offset by margin sensitivity, currency exposure and portfolio execution demands.

The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while the Growth Score of C and Momentum Score of C are more neutral. Because Zacks Style Scores are designed to complement the Zacks Rank, that combination supports a patient stance while investors watch whether stronger growth translates into more durable earnings and margin progress.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

AXQ Capital LP lifted its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 109.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,303 shares of the medical technology company’s stock after purchasing an additional 14,816 shares during the quarter. AXQ Capital LP’s holdings in Medtronic were worth $2,214,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MDT. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the 4th quarter valued at about $27,000. Anfield Capital Management LLC boosted its holdings in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Acumen Wealth Advisors LLC acquired a new stake in Medtronic in the fourth quarter valued at approximately $29,000. Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC purchased a new stake in shares of Medtronic during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Up 1.1% Medtronic stock opened at $94.12 on Friday. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The stock has a market cap of $120.47 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 2.18 and a beta of 0.56. The company’s 50-day moving average price is $86.78 and its two-hundred day moving average price is $85.37. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period last year, the firm posted $1.26 earnings per share. The business’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts expect that Medtronic PLC will post 5.96 EPS for the current fiscal year. Medtronic Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 70.94%.

Trending Headlines about Medtronic Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop. Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own Insider Activity at Medtronic In other news, EVP Harry Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth MDT has been the subject of several analyst reports. Robert W. Baird upped their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Medtronic in a research note on Tuesday, August 18th. The Goldman Sachs Group cut their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Rothschild & Co Redburn decreased their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, BTIG Research raised their target price on Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.92.

Check Out Our Latest Analysis on Medtronic

About Medtronic (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Recommended Stories Five stocks we like better than Medtronic Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday.

Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ dipped 1.40% to 26,001.27. The S&P 500 also fell, dropping, 0.68% to 7,633.51.

Leading and Lagging Sectors

Health care shares jumped by 1.7% on Tuesday.

In trading on Tuesday, consumer discretionary stocks fell by 1.7%.

Top Headline

Medtronic PLC (NYSE:MDT) shares gained around 5% on Tuesday after the company reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.

Medtronic reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $9.756 billion which beat the analyst consensus estimate of $9.545 billion.

Trending

Also, the company announced a $700 million strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.

Equities Trading UP
           

bioAffinity Technologies Inc (NASDAQ:BIAF) shares shot up 66% to $7.59 after the company announced that it is advancing the potential application of its CyPath Lung Test. Shares of Fly-E Group Inc (NASDAQ:FLYE) got a boost, surging 45% to $1.99. Wetour Robotics Ltd (NASDAQ:WETO) shares were also up, gaining 50% to $8.21 after the company announced it released a development demonstration of Orchestra combining surface electromyography with first-person vision to capture richer human-hand data for robot learning. Equities Trading DOWN

Alumis Inc (NASDAQ:ALMS) shares dropped 50% to $10.86 after the company disclosed topline results from Envudeucitinib Phase 2b trial in Systemic Lupus Erythematosus (SLE). Shares of KALA BIO Inc (NASDAQ:KALA) were down 19% to $0.54. Kala Bio and Virotek announced a Letter of Intent to establish an exclusive U.S. distribution partnership for ophthalmology genetic testing program. Nocera Inc (NASDAQ:NCRA) was down, falling 21% to $2.23. Commodities

In commodity news, oil traded up 2.9% to $88.20 while gold traded down 2.3% at $4,376.60.

Silver traded down 3.2% to $64.875 on Tuesday, while copper fell 1.6% to $6.5795.

Euro zone

European shares were lower today. The eurozone’s STOXX 600 slipped 0.5%, while Spain’s IBEX 35 Index fell 0.7%, London’s FTSE 100 fell 0.6%, Germany’s DAX dipped 0.9%, while France’s CAC 40 fell 0.3%.

Asia Pacific Markets

Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 0.15%, Hong Kong’s Hang Seng index declining 0.93%, China’s Shanghai Composite declining 0.16% and India’s BSE Sensex falling 0.02%.

Economics

The US Logistics Managers’ Index declined for a second straight month to a reading of 66.6 in August from 68.9 in the previous month.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Výrobce zdravotnických zařízení Medtronic zveřejnil výsledky za první kvartál fiskálního roku 2027, který skončil 31. července 2026. Tržby i očištěný zisk na akcii překonaly odhady trhu a společnost zároveň zvýšila celoroční výhled organického růstu tržeb i zisku na akcii.

Výsledky společnosti Medtronic (MDT) za 1Q FY 2027   1Q FY 2027 Konsensus 1Q FY2027 1Q FY 2026 Tržby (mld. USD) 9,76 9,54 8,54 Čistý zisk (mld. USD) 1,86 -- 1,63 Očištěný zisk na akcii (EPS, USD/akcie) 1,45 1,39 1,26 Výsledky za 1Q Tržby v prvním kvartále vzrostly meziročně o 13,7 % na 9,76 mld. USD, na organické bázi rovněž o 13,7 %. Do čísel se promítl navíc jeden fiskální týden, jehož přínos k organickému růstu firma odhaduje přibližně na 570 mil. USD.

Očištěná hrubá marže zaznamenala meziroční růst o 10 bazických bodů na 65,2 %. Trh projektoval 64,8 %.

Tržby Medtronicu v 1Q FY 2027 dle segmentů
(v mld. USD) Segment Tržby Konsenzus Meziroční změna Kardiovaskulární 3,93 3,78 +19,5 % Neurověda

2,68 2,66 +10,3 % Lékařsko-chirurgický

2,28 2,25 +10,0 % Diabetologie 0,84 0,82 +16,9 % Tahounem zůstal kardiovaskulární segment, v němž divize Cardiac Ablation Solutions vzrostla o 88 %, v USA dokonce o 139 %, a meziročně získala 9procentních bodů amerického tržního podílu. Cardiac Rhythm Management přidal 15 % a divize Cranial & Spinal Technologies 13 %. Z hlediska regionů rostly tržby v USA organicky o 15,8 % na 4,91 mld. USD, mimo USA o 11,6 % na 4,85 mld. USD.

Očištěná provozní marže dosáhla 23,7 % oproti 23,6 % před rokem, přičemž odhad trhu činil 23,8 %.

V průběhu kvartálu Medtronic dokončil akvizice společností Scientia Vascular a SPR Therapeutics. Zároveň oznámil strategickou investici a distribuční dohodu se společností Cornerstone Robotics týkající se systému Sentire na vybraných trzích mimo USA.

Výhled Společnost zvýšila celoroční výhled a pro fiskální rok 2027 nyní očekává:

Organický růst tržeb o 7,25 až 7,75 %, tedy o 50 bazických bodů více než dosavadních 6,75 až 7,25 %. Očištěný zisk na akcii v rozmezí 5,94 až 6,00 USD oproti předchozím 5,90 až 6,00 USD. Odhad Wall Street byl na úrovni 5,96 USD. Výhled zahrnuje vliv měnových kurzů na zisk na akcii v rozmezí neutrálního dopadu až 1% přínosu, u tržeb naopak negativní dopad 50 až 150 mil. USD.

Výhled také nadále zahrnuje diabetologický segment po celý fiskální rok 2027. Oddělení tohoto byznysu chce společnost dokončit ještě před koncem fiskálního roku a po jeho realizaci výhled aktualizuje.

Komentář vedení „Fiskální rok 2027 jsme zahájili silně. Důvěru nám nedodává pouze samotná síla tohoto kvartálu, ale především šíře výkonnosti napříč našimi obchodními jednotkami a rostoucí příspěvek novějších růstových platforem,“ uvedl generální ředitel Geoff Martha. „Naše realizační schopnost spolu s inovačním motorem nám umožňuje pomáhat většímu počtu pacientů a dosahovat udržitelného růstu. Síla našeho portfolia a připravovaných inovací nám dodává jistotu ohledně příležitostí, které máme před sebou.“

„Nadále cíleně investujeme do inovací, rozvoje portfolia a obchodní realizace, což podpoří udržitelnou dlouhodobou tvorbu hodnoty,“ uvedl finanční ředitel Thierry Piéton. „Kombinace silné provozní výkonnosti a disciplinovaného finančního řízení dostala tržby i očištěný zisk na akcii nad očekávání, což nám umožnilo zvýšit výhled pro fiskální rok 2027.“

Akcie Medtronic Akcie Medtronic (MDT) v předburzovní fázi obchodování posilují o 5,01 % na 95,19 USD.

Michal Bárta, Fio banka, a.s.

Key Takeaways Medtronic expects Q1 growth across Cardiovascular, Neuroscience, MedSurg and Diabetes.MDT's Cardiovascular growth may be led by PFA momentum and strength in Cardiac Rhythm Management.MDT's MiniMed launches and sensor integrations are expected to boost Diabetes revenues. Medtronic plc (MDT - Free Report) is slated to report its first-quarter fiscal 2027 results on Sept. 1, before the opening bell.

The Zacks Consensus Estimate for the company’s first-quarter earnings per share (EPS) suggests 10.3% year-over-year growth to $1.39. The estimate has remained constant in the past 60 days. The consensus mark for first-quarter revenues currently stands at $9.47 billion, implying a 10.4% increase over the prior-year period. 

Image Source: Zacks Investment Research

Medtronic has a solid earnings surprise history, beating estimates in each of the past four quarters, with an average surprise of 2.3%.

Image Source: Zacks Investment Research

Q1 Earnings Whispers for MDTPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.

Earnings ESP: Medtronic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.

Factors Likely to Have Shaped MDT’s Q1 PerformanceCardiovascularThe segment is likely to have witnessed a solid performance across both U.S. and international markets. Within this, Cardiac Ablation Solutions (“CAS”) is expected to have remained the key growth driver, supported by momentum in the pulsed field ablation portfolio, which grew 145% in the previous quarter. The launch of the Sphere-9 catheter in Japan may have also strengthened Medtronic’s position in the region. 

The company has also begun the global rollout of Prism-2, its next-generation mapping software, which offers improved navigation through hybrid impedance and magnetic mapping. In June 2026, Medtronic announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies, which may have provided an additional boost to revenues. 

Cardiac Rhythm Management may also have contributed, driven by Micra leadless pacemakers, Aurora implantable cardioverter defibrillator (EV-ICD) system and the SelectSecure 3830 lead.

In Structural Heart, revenues are expected to have benefited from continued international strength as well as stabilizing U.S. procedure volumes. Growth in the Symplicity Spyral renal denervation system, guide catheters and balloons, as well as Endovenous growth in Peripheral Vascular Health, may have boosted Coronary & Peripheral Vascular sales.

The Zacks Consensus Estimate implies Cardiovascular revenues will increase 15.2% year over year.

NeuroscienceMedtronic continues to invest across its Neuroscience portfolio to advance pipeline innovation and support long-term growth. Within this, Cranial and Spinal Technologies results in the fiscal first quarter may benefit from the continued adoption of the AiBLE ecosystem, with Core Spine and Neurosurgery also likely contributing to growth. The commercial rollout of the Stealth AXiS surgical system may have further advanced. In June, Medtronic received the CE mark for the ear, nose and throat indications, expanding the platform’s reach.

Neuromodulation performance is expected to have been led by the Inceptiv closed-loop spinal cord stimulator, the Percept RC neurostimulator with BrainSense technology, and Interventional products.

Medtronic completed two acquisitions within this business. The Scientia Vascular acquisition in June adds a portfolio of guidewires and catheters to its existing neurovascular product lineup, while the July acquisition of SPR Therapeutics, Inc. (SPR) expands its ability to serve patients across the pain care continuum.

The Zacks Consensus Estimate expects Neuroscience revenues to grow 10.7% year over year.

Medical Surgical (MedSurg)In the fiscal first quarter, MedSurg performance is expected to have been driven by solid growth in Advanced Energy and Wound Management, alongside higher contribution from the Hugo robotic-assisted surgery system. However, similar to recent trends, continued pressure on U.S. bariatric surgery procedure volumes may have partially offset this growth.

Endoscopy is likely to have been a growth driver, with sales benefiting from strong adoption of Endoflip in the United States and Western Europe, as well as from U.S. market share gains of the Nexpowder hemostasis system. Acute Care and Monitoring may have gained from strength in Nellcor pulse oximetry, respiratory and airways and in perioperative.

The Zacks Consensus Estimate for MedSurg’s revenues suggests a 7.6% year-over-year increase.

DiabetesMiniMed, Medtronic’s diabetes business, completed an initial public offering in March, with approximately 10% of its ownership sold and its shares beginning to trade on the Nasdaq Global Select Market. Medtronic continues to hold approximately 90% ownership in MiniMed.

In the first quarter of fiscal 2027, the business is likely to have witnessed robust international contributions from the continued adoption of the MiniMed 780G Automated Insulin Delivery (AID) system, including the Simplera Sync and Guardian 4 continuous glucose monitoring sensors and Extended Infusion Sets. U.S. momentum may also have continued following the late-2025 launches of the Simplera Sync and Abbott’s Instinct sensors. 

The quarter also saw several key developments. MiniMed announced the commercial availability of MiniMed Flex, its smallest app-controlled insulin pump powered by the advanced SmartGuard algorithm. The system is FDA cleared for people with type 1 diabetes aged 7 years and older, as well as adults aged 18 years and older with insulin-requiring type 2 diabetes and is paired with the Simplera Sync sensor. MiniMed Flex is also now available to Medicare and Medicare Advantage beneficiaries.

MiniMed launched the MiniMed 780G system integrated with Abbott’s Instinct sensor and the MiniMed Go system with the Instinct Go sensor in Europe. Together, these developments are expected to have strongly boosted overall revenues in the quarter.

The Zacks Consensus Estimate suggests Diabetes revenues will grow 15.1% year over year.

MDT Stock Price PerformanceOver the past three months, Medtronic shares have outperformed the industry and the broader Medical sector.

Image Source: Zacks Investment Research

The stock has also fared better than major peers like Boston Scientific (BSX - Free Report) , whose shares fell 2%, while Edward Lifesciences (EW - Free Report) gained 4.8%. Boston Scientific’s second-quarter 2026 revenues and EPS surpassed the Zacks Consensus Estimate by 1.1% and 3.6%, respectively. However, the company lowered its 2026 sales and earnings outlook after slower WATCHMAN demand, U.S. electrophysiology share losses and limited operating leverage weakened near-term visibility. Meanwhile, Edwards’ second-quarter revenues and EPS topped the consensus mark by 2.4% and 6.8%, respectively.

MDT’s ValuationMedtronic trades at a forward five-year Price/Earnings (P/E) of 14.98X, lower than its median of 15.73X and the industry average of 17.74X.

Image Source: Zacks Investment Research

EndnoteMedtronic’s upcoming fiscal first-quarter results are expected to reflect ongoing momentum in CAS, as well as strength in businesses such as Cardiac Rhythm Management and Cranial and Spinal Technologies. At the same time, the company is also advancing its M&A and venture initiatives, targeting higher-growth segments to accelerate innovation.

While current indicators do not point to a strong earnings beat, the company has a consistent earnings surprise history, which is encouraging. Medtronic’s recent stock performance has been impressive, outpacing the key benchmarks and peers. Existing MDT shareholders should consider holding their positions, supported by the company’s attractive valuation.  

Key Takeaways Medtronic's Cardiovascular business grew 9.3% organically in fiscal 2026, led by strong rhythm growth.MDT's Hypertension momentum builds as Symplicity Spyral gains access and procedures double after the NCD.Medtronic faces tariff costs and currency risks, with fiscal 2027 guidance signalling a revenue drag. Medtronic plc (MDT - Free Report) is well-poised for growth in the upcoming quarters due to strong momentum in its Cardiovascular businesses, both in the United States and internationally. In Neuroscience, the company is investing across the portfolio to advance pipeline innovation and long-term growth. Medtronic’s Hypertension business could benefit from a large unmet need as renal denervation moves into broader use. Yet, macroeconomic pressures and adverse foreign exchange impacts may weigh on the company’s results.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 0.1% against the industry’s 23.1% decline and the S&P 500 composite’s 20.2% rise.

The renowned medical device company has a market capitalization of $116.67 billion. Medtronic has an earnings yield of 6.5% compared with the industry’s yield of 2.6%. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.3%.

Let’s delve deeper.

Tailwinds for MDTMarket Share Gain Within Cardiovascular to Continue: Medtronic is expanding its global foothold within the Cardiovascular business. Fiscal 2026 Cardiovascular revenues grew 9.3% organically, while fourth-quarter revenues rose 10.1% organically, led by 18.2% growth in Cardiac Rhythm & Heart Failure. Cardiac Ablation Solutions delivered 78% growth, including 124% growth in the United States, and gained 8 U.S. share points.

Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, the SelectSecure 3830 lead, Aurora EV-ICD and OmniaSecure. Peripheral Vascular Health also benefits from the full market release of Liberant mechanical thrombectomy and Neuroguard IEP carotid stenting. These platforms support continued share capture across several cardiovascular categories, while fiscal 2027 commentary calls for Cardiovascular performance broadly in line with fiscal 2026.

Image Source: Zacks Investment Research

Neuroscience Portfolio Shows Growth Prospects: Medtronic’s Neuroscience portfolio remains broad, with growth opportunities across Cranial & Spinal Technologies, Specialty Therapies and Neuromodulation. Fiscal 2026 Neuroscience revenues rose 3.1% organically, and fourth-quarter growth was 3% organically, led by 6% growth in international markets. Within CST, Core Spine grew 6% in the fourth quarter, supported by ModuleX expansion and distributor conversions.

Stealth AXiS secured FDA clearance for spine, cranial and ENT indications and CE Mark for spine and cranial indications, which broadens the platform’s contribution to AiBLE. Specialty Therapies grew 3.4% organically in the fourth quarter, while Neurovascular rose 6% as hemorrhagic products advanced 11% with Neuroguard and Artisse adoption. In Pelvic Health, Altaviva is gaining traction, with active implanters up threefold sequentially and patients treated up 2.5 times. In Neuromodulation, SPR Therapeutics and ViaVerte expand Medtronic’s reach into chronic pain therapies and BVNA.

Hypertension, A New Focus Area: Medtronic’s Hypertension business is entering a broader commercial ramp-up through the Symplicity Spyral renal denervation procedure. The final Medicare National Coverage Determination enabled broader access, and procedure momentum improved after reimbursement clarity. Management noted that average weekly procedures doubled after the NCD, and Symplicity is now annualizing at $100 million.

The company estimates roughly 18 million people in the United States live with uncontrolled hypertension despite multiple medications. Long-term data in more than 2,000 patients showed sustained mean systolic BP reductions of 13.3 millimeters of mercury in ambulatory settings and 18.1 millimeters of mercury in office settings in three years. This evidence, combined with expanding reimbursement and patient demand, supports management’s view that renal denervation can become a multi-billion-dollar opportunity over time.

Downsides for MDTMacroeconomic Issues Hamper Market Growth: Medtronic’s operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. Tariffs impacted the business by 80 basis points (bps) in the fourth quarter of fiscal 2026 after a 110 bps impact in the third quarter. For fiscal 2027, management expects tariff impact on the cost of goods sold (COGS) of approximately $250 million, up $65 million year over year, with no government refund assumed.

Exposure to Currency Movement: Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.

MDT Stock Estimate TrendThe Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has remained constant at $5.94 in the past 30 days.

The consensus estimate for the company’s fiscal 2027 revenues is pegged at $38.64 billion, implying a 6.3% increase from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .

Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.1% against the industry’s 3.5% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 47.8% against the industry’s 3.5% plunge. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 9.9% against the industry’s 3.5% fall over the past year.

Fox Run Management L.L.C. lifted its stake in Medtronic PLC (NYSE:MDT – Free Report) by 364.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,397 shares of the medical technology company’s stock after acquiring an additional 18,364 shares during the period. Fox Run Management L.L.C.’s holdings in Medtronic were worth $1,830,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp lifted its position in shares of Medtronic by 2.0% during the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after buying an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Medtronic by 2.7% during the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after buying an additional 1,419,730 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after buying an additional 3,880,174 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Medtronic by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after buying an additional 231,919 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic News Roundup Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic outperformed the broader market in the latest session, closing higher as investors focused on the company’s defensive medical-device exposure. Medtronic Advances While Market Declines Positive Sentiment: Seventeen analysts have issued targets over the past six months, with a median target of $101, implying additional upside from recent levels. Targets range widely, however, from $83 to $119. Medtronic Analyst Targets and Trading Data Neutral Sentiment: Value-focused coverage is comparing MDT with Agilent Technologies, indicating that investors are evaluating Medtronic’s valuation against peers rather than responding to a major new company-specific catalyst. MDT Versus Agilent for Value Investors Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: 998 investors increased holdings while 1,327 reduced positions, including sizable additions by JPMorgan and reductions by Capital Research and UBS. Medtronic Institutional Activity Negative Sentiment: Quiver estimated CEO Geoff Martha’s 2026 compensation at $22.9 million, up 7.4% year over year. It also reported eight open-market insider sales and no purchases over the past six months, which may raise governance and confidence concerns. Medtronic CEO Compensation and Insider Sales Negative Sentiment: BTIG reaffirmed a “buy” rating but set a $91 price target, below recent trading levels, signaling limited near-term upside in that analyst’s view. BTIG Reaffirms Medtronic Buy Rating Medtronic Stock Up 1.8% MDT stock opened at $92.22 on Wednesday. The stock has a market capitalization of $118.04 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $83.60 and a 200 day moving average of $86.13. Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend The company also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is currently 77.21%.

Wall Street Analyst Weigh In Several research analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Rothschild & Co Redburn lowered their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 21st. Mizuho reduced their price target on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 3rd. Finally, BTIG Research reiterated a “buy” rating and set a $91.00 price objective on shares of Medtronic in a report on Tuesday. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.83.

Read Our Latest Stock Report on Medtronic

Insider Activity In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.26% of the stock is currently owned by insiders.

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Recommended Stories Five stocks we like better than Medtronic The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Posted by Defense World Staff on Aug 11th, 2026

First Bank & Trust purchased a new stake in Medtronic PLC (NYSE:MDT – Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 24,967 shares of the medical technology company’s stock, valued at approximately $1,953,000.

Several other institutional investors also recently made changes to their positions in the stock. Curbstone Financial Management Corp raised its position in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after buying an additional 100 shares during the period. New England Capital Financial Advisors LLC boosted its holdings in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock valued at $135,000 after acquiring an additional 101 shares during the last quarter. Ipsen Advisor Group LLC grew its position in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after acquiring an additional 101 shares during the period. Quadrant Capital Group LLC grew its position in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after acquiring an additional 101 shares during the period. Finally, Rossby Financial LCC increased its stake in Medtronic by 5.1% during the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock worth $211,000 after acquiring an additional 107 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades A number of equities analysts have recently commented on the company. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Monday. BTIG Research reiterated a “buy” rating and set a $91.00 target price on shares of Medtronic in a report on Monday, July 13th. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Sanford C. Bernstein cut their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Finally, Mizuho cut their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average target price of $98.83.

Read Our Latest Analysis on Medtronic

Key Stories Impacting Medtronic Here are the key news stories impacting Medtronic this week:

Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a “turnaround” underway at the company. The upgrade suggests improving execution and renewed confidence in Medtronic’s ability to return to sustainable growth. Is Medtronic Becoming a Turnaround Story? Positive Sentiment: Medtronic is being promoted as an undervalued dividend-growth company, which may attract income-focused investors if the market begins to recognize potential for operational improvement and valuation expansion. Medtronic: Buy This Undervalued Dividend Aristocrat Positive Sentiment: Medtronic’s collaboration with Orchestra BioMed is progressing: the BACKBEAT pivotal trial remains on track to reach its enrollment target by the end of the third quarter of 2026, with primary data expected in the second quarter of 2027. Successful results could support future device-related growth. Orchestra BioMed Reports Second Quarter 2026 Results Neutral Sentiment: Recent coverage highlights Medtronic’s appeal relative to Johnson & Johnson and Abbott, but portrays the company more as a turnaround and valuation opportunity than a consistent high-growth story. Investors may continue to favor peers with stronger near-term organic growth. Johnson & Johnson vs. Medtronic Abbott vs. Medtronic Insider Buying and Selling In related news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.26% of the company’s stock.

Medtronic Stock Up 2.5% Shares of NYSE MDT opened at $89.31 on Tuesday. The stock has a fifty day moving average price of $82.25 and a 200 day moving average price of $86.55. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a market cap of $114.32 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.34 and a beta of 0.55.

Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date was Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Read More Five stocks we like better than Medtronic SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEFocus Financial Network Inc. Has $4.21 Million Stake in Taiwan Semiconductor Manufacturing Company Ltd. $TSM

NEXT HEADLINE »Compound Planning Inc. Sells 7,044 Shares of Microsoft Corporation $MSFT

Posted by Defense World Staff on Aug 7th, 2026

180 Wealth Advisors LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 75.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,951 shares of the medical technology company’s stock after selling 29,822 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Medtronic were worth $778,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic during the 4th quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Acumen Wealth Advisors LLC purchased a new stake in Medtronic in the 4th quarter valued at about $29,000. Imprint Wealth LLC purchased a new stake in Medtronic in the 3rd quarter valued at about $31,000. Finally, Basepoint Wealth LLC purchased a new stake in Medtronic in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 0.1% Shares of NYSE:MDT opened at $85.92 on Friday. The firm has a market capitalization of $109.98 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 2.31 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm’s 50-day moving average is $81.68 and its two-hundred day moving average is $86.68.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were given a dividend of $0.72 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, June 26th. Medtronic’s dividend payout ratio is currently 77.21%.

Analysts Set New Price Targets Several research analysts have weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Mizuho reduced their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC restated a “buy” rating and issued a $101.00 price objective on shares of Medtronic in a report on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and set a $91.00 price objective on shares of Medtronic in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.83.

Read Our Latest Report on Medtronic

Medtronic News Roundup Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic received an expanded CE Mark indication in Europe for its Affera™ Mapping and Ablation System and Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The approval expands the addressable market for the company’s cardiac-ablation technology and supports its international growth strategy. U.S. pivotal-trial enrollment is also underway. Medtronic announces expanded CE Mark indication for Affera and Sphere-9 Positive Sentiment: A bullish investment opinion argues that Medtronic’s medical-device portfolio and long-term growth prospects could support substantial appreciation through the end of 2026. This is an analyst-style opinion rather than a new company announcement, so its effect is likely limited. Medtronic could soar by 40 percent Neutral Sentiment: Medtronic recently exceeded quarterly revenue and adjusted-EPS expectations, reporting $9.81 billion in revenue and $1.55 in EPS. Revenue increased 9.9% year over year, while full-year fiscal 2027 EPS guidance remains $5.90 to $6.00. These results provide a constructive operating backdrop but do not eliminate litigation concerns. Negative Sentiment: A U.S. jury ordered Medtronic to pay $88 million in the first trial involving allegations related to Covidien hernia mesh. Although the award may be manageable relative to Medtronic’s size, the verdict could raise concerns about additional lawsuits, settlement costs and potential reputational damage. Jury says Medtronic owes 88 million dollars in hernia mesh case Insider Buying and Selling at Medtronic In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Further Reading Five stocks we like better than Medtronic Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling 4 Oil and Gas ETF Plays as Prices Stay Sky-High What Tesla Stands to Lose If It Walks Away From China Disney Sets Up for a Magical Year in 2027

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEClark Asset Management LLC Purchases 42,555 Shares of Vanguard Value ETF $VTV

NEXT HEADLINE »Vanguard Growth ETF $VUG Holdings Lifted by Clark Asset Management LLC

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden lowered its stake in Medtronic PLC (NYSE:MDT – Free Report) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,329 shares of the medical technology company’s stock after selling 10,400 shares during the quarter. Andra AP fonden’s holdings in Medtronic were worth $21,951,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in MDT. Madison Asset Management LLC lifted its stake in Medtronic by 25.0% during the 1st quarter. Madison Asset Management LLC now owns 244,000 shares of the medical technology company’s stock worth $21,143,000 after acquiring an additional 48,784 shares in the last quarter. Convergence Investment Partners LLC grew its position in Medtronic by 82.8% in the 1st quarter. Convergence Investment Partners LLC now owns 46,789 shares of the medical technology company’s stock valued at $4,054,000 after acquiring an additional 21,196 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in Medtronic by 9.0% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 46,929 shares of the medical technology company’s stock worth $4,066,000 after purchasing an additional 3,879 shares during the period. Florida Financial Advisors LLC lifted its position in shares of Medtronic by 16.2% during the first quarter. Florida Financial Advisors LLC now owns 3,328 shares of the medical technology company’s stock worth $288,000 after purchasing an additional 465 shares in the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. boosted its stake in shares of Medtronic by 1.4% in the first quarter. Leith Wheeler Investment Counsel Ltd. now owns 323,384 shares of the medical technology company’s stock valued at $28,021,000 after purchasing an additional 4,540 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Up 0.1% Medtronic stock opened at $83.29 on Tuesday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a market cap of $106.61 billion, a PE ratio of 22.33, a P/E/G ratio of 2.23 and a beta of 0.56. The stock’s fifty day moving average is $79.68 and its two-hundred day moving average is $87.84.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the previous year, the business earned $1.62 EPS. Medtronic’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Insider Activity In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages recently weighed in on MDT. Barclays upped their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Argus cut their price objective on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. The Goldman Sachs Group reduced their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $85.00 target price on shares of Medtronic in a report on Tuesday, June 16th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $98.21.

Read Our Latest Research Report on Medtronic

Medtronic Company Profile (Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

See Also Five stocks we like better than Medtronic The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Purchases 53,990 Shares of Thermo Fisher Scientific Inc. $TMO

NEXT HEADLINE »Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY

It has been about a month since the last earnings report for Medtronic (MDT - Free Report) . Shares have added about 1.5% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

Medtronic's Q4 Earnings & Revenues Top EstimatesMedtronic plc posted fourth-quarter fiscal 2026 adjusted earnings of $1.55 per share, down 4.3% from the year-ago quarter but above the Zacks Consensus Estimate by 0.6%.

For the full-year fiscal 2026, adjusted earnings per share was $5.53, up 0.7% year over year. The figure missed the Zacks Consensus Estimate by 0.2%.

Revenue rose 9.9% year over year to $9.81 billion and beat the consensus by 1.5%. The upside came as procedure-driven demand stayed firm across key franchises. Cardiac Ablation Solutions revenue surged 78% globally, including 124% growth in the United States, while multiple portfolios delivered healthy gains.

Full-year worldwide revenues totaled $36.4 billion, up 8.4% year over year. The top line marginally surpassed the Zacks Consensus Estimate by 0.6%.

MDT’s Portfolio Mix Tilted Toward Cardiovascular

Cardiovascular generated $3.80 billion in the quarter, underscoring the importance of the company’s largest portfolio to overall momentum. Neuroscience contributed $2.75 billion, and Medical Surgical added $2.39 billion, reflecting steady demand across hospital-based therapy areas.

Diabetes produced $837 million of revenue and remained a meaningful growth lever alongside the broader portfolios. The mix shows Medtronic’s exposure to both large, recurring procedural categories and faster-moving product cycles in areas like diabetes management.

MDT’s Geographic Split Favored International Growth

U.S. revenue increased 7.1% year over year to $4.87 billion, supported by gains across major portfolios and continued procedure volume resilience.

International revenue advanced 12.8% to $4.94 billion. The overseas outperformance was broad-based and included a notable lift in Diabetes internationally, reinforcing how global scale can amplify Medtronic’s reported results when demand is healthy.

Medtronic’s Adjusted Margins Mixed in the Quarter

On an adjusted basis, Medtronic posted gross margin of 65.4% in fourth-quarter fiscal 2026, up 30 basis points year over year, reflecting a modest improvement in profitability at the product level.

However, operating leverage moved the other way. The adjusted operating margin fell to 25.5%, down 230 basis points from the prior-year quarter, as the company absorbed notable headwinds, including margin impacts tied to the MiniMed Blackstone payment and tariffs.

Medtronic’s Cash Generation Supports Returns and Investment

Operating cash flow totaled $7.33 billion in fiscal 2026, providing the financial flexibility to fund both portfolio investment and shareholder distributions. Free cash flow was $5.43 billion for the year, equal to 76% free cash flow conversion from adjusted net earnings.

Medtronic also returned $4.2 billion to shareholders in fiscal 2026 and ended the year with $9.2 billion in cash and investments.

Medtronic’s FY27 Guidance and Shareholder Returns

Looking ahead, the company guided for fiscal 2027 organic revenue growth of 6.75% to 7.25% and adjusted earnings of $5.90 to $6.00 per share. The outlook bakes in the benefit of a 53rd week, additional M&A and a full-year contribution from the Diabetes business, while also considering tariffs, interest and tax expense. The Zacks Consensus Estimate projects fiscal 2027 revenues of $38.39 billion, up 6.1% from fiscal 2026 levels, while earnings per share is expected to rise 9.7% to $6.08.

Medtronic also increased its quarterly dividend to $0.72 per share, implying an annual rate of $2.88 and marking its 49th consecutive year of dividend increases.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates revision.

VGM ScoresCurrently, Medtronic has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Medtronic has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.